EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold

Kai Xu, Guosheng Fu, Xiaozeng Wang, Lei Song, Ling Tao, Lang Li, Yuqing Hou, Xi Su, Quan Fang, Lianglong Chen, Huiliang Liu, Bin Wang und 8 weitere

JACC: Cardiovascular Interventions · 2025-09 · 18 (17) · 2107-2115

DOI: 10.1016/j.jcin.2025.06.036 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-09. Verfasst von Kai Xu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China. Hauptthemen laut MEDLINE: Absorbable Implants, Coronary Artery Disease, Percutaneous Coronary Intervention, Cardiovascular Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Absorbable ImplantsCoronary Artery DiseasePercutaneous Coronary InterventionCardiovascular AgentsSirolimusDrug-Eluting StentsEverolimusCoronary VesselsCoated Materials, BiocompatibleHumansMaleFemaleMiddle AgedTreatment OutcomeTime FactorsTomography, Optical CoherenceProsthesis DesignAgedChromium AlloysRisk FactorsFractional Flow Reserve, MyocardialCoronary ThrombosisCoronary AngiographyPolyestersKaplan-Meier Estimate

Stichwörter der Autor:innen

bioresorbable scaffoldcoronary artery diseasepercutaneous coronary interventionsirolimus-eluting stent(s)

Substanzen

Cardiovascular AgentsSirolimusChromium AlloysEverolimusPolyestersCoated Materials, Biocompatiblepoly(lactide)

Autor:innen und Institutionen

  • Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
  • Department of Cardiology, Sir Run Run Shaw Hospital, Hangzhou, China.
  • Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Cardiology, Xijing Hospital, the Fourth Military Medical University, Xi'an, China.
  • Department of Cardiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Cardiology, Nanfang Hospital, Guangzhou, China.

Zitieren

APA

Xu, K., Fu, G., Wang, X., Song, L., Tao, L., Li, L., Hou, Y., Su, X., Fang, Q., Chen, L., Liu, H., Wang, B., Yuan, Z., Gao, C., Zhou, S., Guan, C., Li, Y., Han, Y., Stone, G. W., & NeoVas Randomized Controlled Trial Investigators (2025). 5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 18(17), 2107-2115. https://doi.org/10.1016/j.jcin.2025.06.036

Vancouver

Xu K, Fu G, Wang X, Song L, Tao L, Li L, et al. 5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold. JACC: Cardiovascular Interventions. 2025;18(17):2107-2115. doi:10.1016/j.jcin.2025.06.036

BibTeX
@article{Xu2025,
  author = {Xu, Kai and Fu, Guosheng and Wang, Xiaozeng and Song, Lei and Tao, Ling and Li, Lang and Hou, Yuqing and Su, Xi and Fang, Quan and Chen, Lianglong and Liu, Huiliang and Wang, Bin and Yuan, Zuyi and Gao, Chuanyu and Zhou, Shenghua and Guan, Changdong and Li, Yi and Han, Yaling and Stone, Gregg W and NeoVas Randomized Controlled Trial Investigators, NeoVas Randomized Controlled Trial Investigators},
  title = {5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {17},
  pages = {2107--2115},
  doi = {10.1016/j.jcin.2025.06.036}
}
Kostenlos starten →